IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Trial record 1 of 1 for:
NCT01963429
Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC
This study is currently recruiting participants.
Verified March 2015 by Joong-Won Park, National Cancer Center, Korea
Sponsor:
National Cancer Center, Korea
Information provided by (Responsible Party):
Joong-Won Park, National Cancer Center, Korea
ClinicalTrials.gov Identifier:
NCT01963429
First received: October 13, 2013
Last updated: March 22, 2015
Last verified: March 2015
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This phase 3 study is to evaluate the effectiveness of the comparison between radiofrequency ablation and hypofractionated proton beam radiation.
| Condition | Intervention | Phase |
|---|---|---|
| Recurrent Small Hepatocellular Carcinoma Residual Small Hepatocellular Carcinoma | Radiation: Proton beam therapy | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomized Phase III Study of the Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation in Patients With Recurrent/Residual Small Hepatocellular Carcinoma (APROH Study) |
Further study details as provided by Joong-Won Park, National Cancer Center, Korea:
Primary Outcome Measures:
- local progression-free survival(LPES) [ Time Frame: up to 2 year ]To evaluate the local progression-free survival (1cm from ablation cavity or 1.5cm form gross tumor) for 2 years
Secondary Outcome Measures:
- disease-free survival (DFS) [ Time Frame: up to 2 years until study closed ]Disease-free survival was defined as the interval from the date of randomization to date of detection study closed
Other Outcome Measures:
- overall survival (OS) [ Time Frame: up to 2 years until study closed ]Overall survival(OS) was defined as the interval from the date of randomization to date of detection study closed
| Estimated Enrollment: | 144 |
| Study Start Date: | October 2013 |
| Estimated Study Completion Date: | December 2018 |
| Estimated Primary Completion Date: | December 2018 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
Experimental: Arm A (RFA)
|
Radiation: Proton beam therapy |
|
Experimental: Arm B (Proton)
66 GyE /10 fx, 6.6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30<40%,and/or RLV30<30%)
|
Radiation: Proton beam therapy |
Detailed Description:
The sample size for this study was based on a non-inferiority design. Primary objective: estimate local progression-free survival (LPFS) rate in two treatments Primary endpoint: 2-year LPFS rate Expected 2-year LPFS rate in the RFA: 85% Accural time and follow up time: 24 months and 24 months, respectively. Precision for 2-year LPFS rate estimation: Allowing a difference of 15% as the non-inferiority margin, with a power of 80% and a type I error level of 5%, evaluable 68 patients are required.
Considering 5% of follow-up loss, we need 72 patients in each arm, so a total of 144 patients will be enrolled.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- HCC diagnosed as (i) the presence of risk factors including hepatitis B or C virus and liver cirrhosis, a serum a-fetoprotein (AFP) level greater than 200 IU/ml and a radiologically compatible feature with HCC in one or more CT/MRI/angiograms, or (ii) the presence of risk factors including hepatitis B or C virus and liver cirrhosis, a serum a-fetoprotein (AFP) level less than 200 IU/ml, and a radiologically compatible feature with HCC in two or more CT/MRI/angiograms or (iii) histological confirmation
- HCC patients who had recurrent or residual tumor after other treatments
- without evidence of extrahepatic metastasis
- the largest diameter of tumor should be less than 3cm, and the number of tumor ≤2
- no previous treatment to target tumors by other forms of RT
- liver function of Child-Pugh class A or B7 (Child-Pugh score of ≤7)
- Age of ≥18 years
- performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) score
- WBC count ≥ 2,000/mm3; hemoglobin level ≥ 7.5 g/dL; platelet count ≥ 50,000/mm3; and adequate hepatic function (total bilirubin ≤ 3.0 mg/dL; AST and ALT < 5.0× upper limit of normal; no ascites)
- no serious comorbidities other than liver cirrhosis
- written informed consent
Exclusion Criteria:
- evidence of extrahepatic metastasis
- age < 18 years
- liver function of Child-Pugh class B8-9 and C (Child-Pugh score of >7) or uncontrolled cases of active chronic hepatitis B
- previous history of other forms of RT adjacent to target tumors
- poor performance status of 3 to 4 on the Eastern Cooperative Oncology Group (ECOG) score
- pregnant or breast feeding status
- previous history uncontrolled other malignancies within 2 years
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01963429
Please refer to this study by its ClinicalTrials.gov identifier: NCT01963429
Contacts
| Contact: Joong Won Park, Ph.D | +82-31-920-1605 | jwpark1@ncc.re.kr | |
| Contact: Tae Hyun Kim, Ph.D | +82-31-920-1725 | k2onco@ncc.re.kr |
Locations
| Korea, Republic of | |
| National Cancer Center, Korea | Recruiting |
| Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769 | |
| Contact: Joong Won Park, Ph.D +82-31-920-1605 jwpark1@ncc.re.kr | |
| Contact: Tae Hyun Kim, Ph.D +82-31-920-1725 k2onco@ncc.re.kr | |
| Sub-Investigator: Tae Hyun Kim, Ph.D | |
| Sub-Investigator: Young Hwan Koh, Ph.D | |
| Sub-Investigator: Ju Hee Lee, Ph.D | |
| Sub-Investigator: Chang Min Kim, Ph.D | |
| Sub-Investigator: Bo Hyun Kim, Ph.D | |
| Sub-Investigator: Min Ju Kim, Ph.D | |
| Sub-Investigator: Bung Ho Nam, Ph.D | |
Sponsors and Collaborators
National Cancer Center, Korea
Investigators
| Principal Investigator: | Joong Won Park, Ph.D | National Cancer Center, Korea |
More Information
| Responsible Party: | Joong-Won Park, Principal Investigator, National Cancer Center, Korea |
| ClinicalTrials.gov Identifier: | NCT01963429 History of Changes |
| Other Study ID Numbers: |
NCCCTS 13-695 |
| Study First Received: | October 13, 2013 |
| Last Updated: | March 22, 2015 |
Keywords provided by Joong-Won Park, National Cancer Center, Korea:
|
hepatocellular Proton RFA |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma |
Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases |
ClinicalTrials.gov processed this record on August 16, 2017